l e t t e r s
Although genome-wide association studies (GWAS) have identified the existence of numerous population-based cancer susceptibility loci, mechanistic insights remain limited, particularly for intergenic polymorphisms. Here, we show that polymorphism at a remote intergenic region on chromosome 11q13.3, recently identified as a susceptibility locus for renal cell carcinoma 1 , modulates the binding and function of hypoxia-inducible factor (HIF) at a previously unrecognized transcriptional enhancer of CCND1 (encoding cyclin D1) that is specific for renal cancers characterized by inactivation of the von Hippel-Lindau tumor suppressor (pVHL). The protective haplotype impairs binding of HIF-2, resulting in an allelic imbalance in cyclin D1 expression, thus affecting a link between hypoxia pathways and cell cycle control.
Kidney cancer (renal cell carcinoma (RCC)) accounts for more than 100,000 deaths per year worldwide 2 . More than 80% are clear cell tumors (ccRCCs), and most are associated with loss of function of pVHL 3, 4 . pVHL is a ubiquitin ligase that promotes oxygen-dependent degradation of HIF-1α and HIF-2α by recognizing hydroxylated prolyl residues in HIF-α (refs. 5-7) . Loss of pVHL function upregulates HIF-α subunits and activates HIF-dependent transcriptional pathways. The frequency but uncertain or poorly understood causality of dysregulated hypoxia pathways in cancer has raised fundamental questions as to whether and by what means the HIF pathway contributes to ccRCC. A range of other (non-HIF) functions have been identified for pVHL 8 that may contribute to tumor suppressor behavior, but gene transfer and knockdown studies point to a role for HIF-2 but not HIF-1 in the progression of ccRCC xenografts [8] [9] [10] [11] [12] [13] . However, to date, there has been little evidence from human genetic studies of a direct causal role for HIF in sporadic ccRCC. Genetic analyses of RCC tumor material have not identified activating mutations in EPAS1 (encoding HIF-2α) and, unexpectedly, the only genetic alterations in genes encoding HIF subunits have been inactivating mutations or deletions of HIF1A (encoding HIF-1α) [13] [14] [15] [16] .
A recent GWAS discovered two SNPs in intron 1 of EPAS1 that were significantly associated with increased RCC risk; however, no functional studies were performed 1 . In the same study, a second RCC susceptibility locus was identified in an intergenic region of unknown function at 11q13.3, a finding that has recently been replicated in other populations 17, 18 . As part of an ongoing study to define the direct transcriptional targets of HIF-2 in renal cancer, we undertook a genome-wide analysis of HIF-2-binding sites in pVHL-defective 786-O cells (which lack functional HIF-1α owing to a truncated transcript 13 ) using chromatin immunoprecipitation (ChIP) with antibodies to HIF-2α and its dimerization partner HIF-1β coupled to high-throughput sequencing (ChIP-seq).
Among ~600 pangenomic HIF-2 ChIP signals, we observed strong binding (ranked twelfth by peak height) almost precisely coinciding with the RCC predisposition SNP rs7105934 at 11q13.3. The strongest signal (H) was 5 kb centromeric to rs7105934 (chr. 11: 68943716-68944005). There were more minor signals immediately adjacent (h1) and more distal (h2) to this region (Fig. 1a) . None of these regions bound HIF subunits in a previous ChIP-seq analysis in pVHL-competent MCF-7 breast cancer cells 19 . Analysis of data from Europeans in the 1000 Genomes project showed that the major ChIP-seq signal (H) overlapped polymorphic nucleotides rs7948643, rs7939721 and rs7939830, whereas the weaker signal (h2) overlapped rs17136556, rs77247065 and rs11263441. Pairwise linkage disequilibrium (LD) of all these SNPs and the RCC-associated SNP rs7105934 was reported to be high (r 2 = 1; from 1000 Genomes Pilot 1 data). To confirm this directly, we genotyped at each SNP a larger cohort of 192 cancer-free individuals from the UK and confirmed strong LD (r 2 ranging from 0.77 to 1), especially between rs7105934 and SNPs overlying the strongest HIF-2 ChIP signal (Fig. 1a) . Sequence inspection indicated that sites H and h2 but not h1 contained consensus hypoxia-responsive element (HRE) motifs (RCGTG; Supplementary Fig. 1) . ChIP followed by quantitative PCR (ChIP-qPCR) confirmed robust binding of HIF-2α and HIF-1β
Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression l e t t e r s at the major site (H) in both 786-0 cells and human RCC tissue, whereas signals at h2 were much less robust, particularly for HIF-2α (Fig. 1b,c and data not shown). Thus, LD at the intergenic 11q13.3 RCC risk-associated locus extends across a region of robust HIF-2-binding (H) in RCC.
As this locus is remote from the nearest annotated gene and lacks CpG islands associated with gene promoters, we examined whether the major HRE-containing site (H) had the epigenetic characteristics of a transcriptional enhancer. First, we looked for reduced nucleosome occupancy using formaldehyde-assisted isolation of regulatory elements (FAIRE) 20 . This revealed a region of reduced nucleosome occupancy extending over approximately 2 kb around the HIFbinding site in 786-0 cells but not in MCF-7 cells, (Fig. 2a) . Second, in Fold enrichment 10
o t e r C o n t r o l r e g io n c 10,000 npg l e t t e r s 786-0 cells but not MCF7 cells we observed high levels of monomethylated histone H3 at lysine 4 (H3K4me1) and acetylated H3 at lysine 27 (H3K27ac), with low levels of trimethylated histone H3 at lysine 4 (H3K4me3). This combination of histone modifications is observed at active enhancers (compare to the NDRG1 enhancer) but not promoters (compare to the FAM13A promoter) [21] [22] [23] (Fig. 2b-d) .
As expected for an active enhancer, in 786-0 cells, there was a low-level ChIP-qPCR signal for RNA polymerase II (RNA Pol II), which is consistent with interaction with the transcriptional apparatus 21 (Fig. 2e) . Finally, in 786-O cells, expression of a reporter gene (pGL3-Promoter luciferase) was enhanced by these sequences and attenuated by mutation of the HRE (Fig. 2f) . Taken together, these data indicate that the 11q13.3 RCC susceptibility locus overlaps a HIF-dependent transcriptional enhancer.
Genome-wide expression analysis in 786-O cells and renal tumors identified CCND1 (encoding cyclin D1), which flanks the site of interest and lies 220 kb telomeric to the enhancer, as one of the most HIF-regulated genes on chromosome 11 ( Supplementary Fig. 2a,b) . CCND1 is an oncogene that is commonly upregulated in cancer, including RCC [24] [25] [26] (Supplementary Fig. 2c ). Previous studies have defined CCND1 as a HIF-regulated gene in 786-0 and other RCC cell lines but were unable to map the control sequences 10,27-30 .
These analyses revealed notable cell type specificity; that is, CCND1 is responsive to HIF-2α in RCC cells but not in any other cell line analyzed.
We then tested whether this tight cell type specificity was reflected in HIF-2 binding and the epigenetic enhancer marks at the 11q13.3 susceptibility locus. Both DNA accessibility, as determined by FAIRE, and HIF-2 binding, assessed by ChIP-qPCR, were similarly cell type specific, being present in all pVHL-defective RCC cell lines tested but absent across cell lines expressing wild-type pVHL (including cancerous (Caki-1) and noncancerous (HK-2 and HKC-8) renal epithelial cells) (Fig. 3a,b) , despite comparable levels of HIF-2α induced by hydroxylase inhibition (Supplementary Fig. 3a) . We observed similar cell type-specific patterns of HIF-1 binding: HIF-1 binding occurred in all pVHL-defective RCC cell lines that expressed this isoform but was absent in all cell lines expressing wild-type pVHL ( Supplementary  Fig. 3c) . Furthermore, consistent with previously reported patterns of CCND1 expression in RCC cell lines, the 11q13.3 enhancer remained accessible and able to bind HIF following reintroduction of wildtype pVHL into pVHL-defective RCC cells (786-0/VHL cells) 19, 27 ( Fig. 3c,d) . Thus, constitutively high levels of HIF are not required to maintain the activity of this region as an enhancer, but it is a stable feature of cell lines derived from pVHL-defective RCC. 
npg l e t t e r s
Exact concordance between the existence of the HIF-binding enhancer and the regulation of cyclin D1 by HIF strongly suggested that the 11q13.3 locus encodes a long-range enhancer that physically associates with the CCND1 promoter to regulate transcription. To test this, we used two assays of physical association between distant genetic loci: high-resolution FISH and chromatin conformation capture (3C) 31 . Both techniques provided evidence for physical association of the HIF-binding enhancer with the CCND1 promoter in 786-O cells but not in MCF-7 cells (Fig. 4 and Supplementary Fig. 4 ). Although our analysis does not exclude the possibility that the enhancer regulates additional genes, we conclude that the 11q13.3 susceptibility locus overlaps a cell type-specific long-range enhancer of cyclin D1 expression.
We next examined the effect of variants at 11q13.3 on the enhancer and on expression of CCND1. We first genotyped a number of pVHLdefective ccRCC cell lines at rs7105934, rs7948643 and rs77247065 and found one, KTCL140, to be heterozygous at all three SNPs (and at the remaining four SNPs covered by the other ChIP-seq peaks) with normal copy number and equal allelic dosage ( Supplementary  Fig. 5 ). Allele-specific analysis of immunoprecipitated chromatin in this cell line showed preferential binding of both HIF-2α and HIF-1β to the major (RCC-predisposing) allele at rs7948643 (Fig. 5a) . ChIP using an antibody to RNA Pol II also showed that the major allele at this locus preferentially interacted with the basal transcriptional machinery (Fig. 5b) . Furthermore, similar analysis of material prepared from KTCL140 cells by FAIRE indicated a greater npg l e t t e r s degree of chromatin accessibility with the major allele at this locus (Fig. 5c) . Thus, the minor (RCC-protective) allele at 11q13.3 disrupts HIF binding, DNA accessibility and interaction with the transcriptional apparatus at the CCND1 enhancer. We then determined whether these allele-specific effects at the CCND1 enhancer alter the allelic balance of CCND1 expression. We identified heterozygous SNPs (rs7177 and rs678653) within the 3′ UTR of CCND1 in KTCL140 cells. These SNPs are in weak LD with SNPs at the HIF-binding site (for the tag SNP rs7105934, pairwise LD with rs7177, r 2 = 0.02, D′ = 0.51 and with rs678653, r 2 = 0.00, D′ = 0.08). The phase in KTCL140 cells is therefore unknown. However, mRNA from these cells showed distinct (P < 1 × 10 −3 ) allelic imbalance compared to genomic DNA ( Fig. 5d and Supplementary  Fig. 6a ). Furthermore, we observed similar allelic imbalance in binding of RNA Pol II to this coding region ( Fig. 5e and Supplementary  Fig. 6b ). These results are therefore consistent with the prediction of differential CCND1 expression arising from the two 11q13.3 alleles in these cells.
Taken together, these findings indicate that the activity of a promoterdistant enhancer of CCND1 that binds HIF-2 in renal cancer is reduced by the protective haplotype at the 11q13.3 RCC-susceptibility locus. Given the established role of cyclin D1 as an oncogenic cell cycle regulator 26 , this provides a plausible mechanism for the observed susceptibility effects. High LD in this region makes it difficult to distinguish the causative polymorphism(s) genetically. Although two of the SNPs in the susceptibility haplotype (rs7948643 and rs7939721) lie only 10 bp and 15 bp from the HIF-binding motif at 11q13.3 (H), respectively, neither disrupts the core RCGTG sequence. Thus, whether the minor allele affects HIF binding directly or indirectly by altering local chromatin structure remains to be determined. Notably, although, as with most HIF-binding sites, the enhancer can bind both HIF-1 and HIF-2, functional studies of CCND1 expression suggest that only HIF-2 is transcriptionally active 10 , a result which is in keeping with transcriptional selectivity among HIF isoforms being conferred by mechanisms triggered following DNA binding 32, 33 .
Although we have not tested every cell with wild-type pVHL, the enhancer activity seems to be restricted to pVHL-defective RCC cells but is not reversed by reintroduction of pVHL, suggesting that it is a specific feature of the pVHL-defective RCC background. This raises questions as to when during RCC development the susceptibility effect operates and whether it contributes to the tissue specificity of pVHL tumor suppressor behavior. Kidneys of individuals with von Hippel-Lindau disease (the principal familial form of RCC) contain many tiny precursor lesions representing foci of biallelic VHL inactivation 34 . These manifest upregulation of the HIF pathway. However, only a minority express EPAS1 and CCND1, and this pattern is strongly associated with dysplastic morphology 10 . This suggests several possibilities, at least in this form of RCC. First, the HIF-2-CCND1 link may result from a 'second hit' occurring after biallelic VHL inactivation (perhaps owing to epigenetic alterations creating a 'neo-enhancer ' (refs. 15,16,35,36) ). Secondly, the unusual connection between the HIF pathway and CCND1 could be an intrinsic property of a rare population of cells in the renal tubular epithelium that are then selected following dysregulation of the VHL-HIF pathway. Alternatively, a third possibility is that stable epigenetic changes are effected as a result of long-term HIF activation following pVHL inactivation and that these are not reversible upon re-expression of wild-type pVHL.
The finding that both major RCC-predisposition loci defined by GWAS at 2p21 (EPAS1 encoding HIF-2α) and 11q13.3 affect specific components of hypoxia pathways suggests that particular aspects of hypoxia pathway dysregulation (as opposed to general upregulation) are important in RCC development. A third locus at 12q24.31 (within intron 1 of SCARB1) that was implicated in the original GWAS but not robustly in the replication cohorts 1 lies within 2 kb of an additional HIF-binding site identified in multiple cell types ( Supplementary  Fig. 7) . However, LD with the candidate SNP at 12q24.31 did not extend over this HIF-binding region, indicating that, if this is an RCC predisposition locus, it is unlikely to operate through direct effects on HIF binding per se. Nevertheless, consideration of other GWAS signals in light of our pan-genomic analysis of HIF binding in RCC may yield further insights into the role of hypoxia pathways in RCC predisposition.
URLs. 1000 Genomes Project, http://www.1000genomes.org/; CisGenome, http://www.biostat.jhsph.edu/~hji/cisgenome/; Haploview, http://www.broadinstitute.org/scientific-community/ science/programs/medical-and-population-genetics/haploview/ haploview; CisGenome software suite, http://www.biostat.jhsph. edu/~hji/cisgenome/; ImageJ, http://rsbweb.nih.gov/ij/.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. HIF ChIP-seq data have been deposited in the Gene Expression Omnibus, including data from 786-O cells (GSE34871) and MCF-7 cells (GSE28352).
analogous to conventional qRT-PCR for mRNA expression levels based on a standard curve. This provided confirmatory evidence of the shift in allelic dosage found by TaqMan-based SNP analysis (data not shown). DNA from the KTCL140 cell line was also genotyped using the Illumina OmniExpress SNP array according to the manufacturer's protocols. Data were analyzed using the Illumina Genomestudio software. Data analysis. Statistical analyses for FISH measurements were performed using IBM SPSS Statistics version 19. Statistical analyses for FAIRE and ChIP results were performed using a one-sample t test, comparing the mean with a hypothetical value of 1 using GraphPadPrism Version 4.00. All other analyses were conducted using a one-way Anova with Dunnett's post test.
